Close Menu

NEW YORK – Belgian oncology molecular diagnostics firm Biocartis reported before the opening of the market today that its revenues for the first half of 2019 rose 39 percent year over year, driven by increases in product sales and collaboration revenues.

For the six months ended June 30, Biocartis' revenues rose to €17.1 million ($18.9 million) from €12.3 million in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.